Orange County Research Center

The trials here

What the 18 trials at this site are about, from their registry records.

Conditions

• Obesity10 trials
• Type 2 diabetes6 trials
• Chronic kidney disease2 trials
• High blood pressure2 trials
• Asthma1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Heart failure1 trial
• Sickle cell disease1 trial
• Type 1 diabetes1 trial

Phase

• Phase 27 trials
• Phase 16 trials
• Phase 35 trials

Status

• Recruiting7 trials
• Completed5 trials
• Active, not recruiting4 trials
• Terminated1 trial
• Withdrawn1 trial

Lead sponsor

• Amgen6 trials
• Eli Lilly and Company4 trials
• Hoffmann-La Roche3 trials
• Pfizer3 trials
• E-Star BioTech, LLC1 trial
• and 1 more

Running trials

• Recruiting

  A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  NCT07794579· Phase 3· Eli Lilly and Company· Source

  Contact: JOEL NEUTEL (principal investigator)

• Recruiting

  A Study to Learn How Different Amounts of the Study Medicine Called PF-08642534 Are Tolerated and Act in the Body of People Who Have Obesity

  NCT07731139· Phase 1· Pfizer· Source

• Recruiting

  A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

  NCT07590193· Phase 1· Amgen· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  NCT07351058· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

  Contact: JOEL NEUTEL (principal investigator)

• Recruiting

  A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes

  NCT07112872· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

  NCT06991257· Phase 2· Pfizer· Source

• Recruiting

  To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension

  NCT06343298· Phase 2· E-Star BioTech, LLC· Source

  Contact: BOLD-HTN, BSME

• Active, not recruiting

  A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

  NCT06660173· Phase 2· Amgen· Source

• Active, not recruiting

  A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

  NCT06637371· Phase 1· Amgen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity3 recruiting
• Type 2 diabetes3 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• High blood pressure1 recruiting
• Type 1 diabetes1 recruiting

Closed trials

• Completed

  A Study Evaluating the Effect of Daily Oral Tifeglipron (RO7795081) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

  NCT07081958· Phase 2· Hoffmann-La Roche· Source

• Withdrawn

  A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

  NCT06901349· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)

  NCT06864104· Phase 2· Kardigan, Inc.· Source

• Completed

  A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body

  NCT07429045· Phase 1· Amgen· Source

• Completed

  Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

  NCT06585462· Phase 1· Amgen· Source

• Terminated

  Study of GBT021601 in Participants With Renal Impairment

  NCT05878704· Phase 1· Pfizer· Source

• Completed

  A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

  NCT05803421· Phase 3· Eli Lilly and Company· Source